Plus Therapeutics Says CNSide Leptomeningeal Metastases FORSEE Trial Met Key Primary And Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics announced that its CNSide Leptomeningeal Metastases FORSEE Trial met key primary and secondary endpoints. The trial demonstrated that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target. The data were presented at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Metastases Conference.
August 13, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Plus Therapeutics' CNSide Leptomeningeal Metastases FORSEE Trial met key primary and secondary endpoints, significantly influencing treatment decisions in over 90% of cases. This positive outcome was presented at a major oncology conference.
The successful trial results and their presentation at a major conference are likely to boost investor confidence and positively impact the stock price of Plus Therapeutics in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100